News center More...

04 2025-01
Conference Express |Gluetacs Therapeutics Will Attend the 2025 J.P. Morgan & BIOTECH SHOWCASE Annual International Conference
28 2024-12
Good news! Gluetacs Therapeutics won Top 100 of the Shanghai High-Value Patent Operation Competition and awarded the title of Director Unit of the National Biopharmaceutical Enterprise Platform
24 2024-12
Gluetacs was honored with 2024 Shanghai high-tech enterprises and 2024 Special Fund for Promoting the Integration of Industry and Education in the Lingang Special Area of the China (Shanghai) Pilot Free Trade Zone
23 2024-12
Gluetacs Therapeutics Co-reported PARP1 Degrader Demonstrating Superior Safety and Efficacy in BRCA-Deficient Tumors Published in Cell Death & Disease
13 2024-12
Gluetacs Therapeutics has co-published a paper in Nature Communications, reporting on CDK9-targeted degraders and their application in the treatment of cutaneous T-cell lymphoma
27 2024-11
Another Honor | Gluetacs Wins the Finalist Award at the 4th Biopharma “Rising Star” Competition
10 2024-11
University-Industry Integration | Gluetacs Successfully Selected for Lingang New Area College Student Internship Base List